ArticleScientific reports2025
Cathepsin B in human peripheral blood lymphocytes as a peripheral biomarker for cardiac hypertrophy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Previous studies have demonstrated that cathepsin B is up-regulated in the myocardium of both mice and humans with pathological cardiac hypertrophy. However, it remains unknown whether cathepsin B is detectable in human peripheral blood lymphocytes (PBLs) and whether its expression is associated with pathological hypertrophy. In this study, immunofluorescence staining confirmed the presence of cathepsin B in human PBLs. Western blotting analysis and correlation studies further revealed a positive correlation between cathepsin B protein levels in PBLs and that in cardiac tissues (r = 0.441, p = 0.017). We also investigated the association between cathepsin B expression level in PBLs and cardiac structure and function. Quantitative PCR and western blotting analyses indicated that patients with left ventricular hypertrophy, particularly those with eccentric hypertrophy, exhibited significantly elevated cathepsin B expression in PBLs (p < 0.001). Logistic regression analysis identified cathepsin B as an independent risk factor for left ventricular hypertrophy (odds ratio = 4.863, 95% confidence interval: 1.341-17.632). Receiver operating characteristic analysis further supported its diagnostic value (area under the curve = 0.748, p = 0.001). In summary, cathepsin B levels in PBLs positively correlates with myocardial levels and may serve as a peripheral biomarker for diagnosing maladaptive cardiac hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.